Xencor (NASDAQ:XNCR) Sees Large Volume Increase – Here’s What Happened

Xencor, Inc. (NASDAQ:XNCR) shares saw unusually-strong trading volume on Monday . Approximately 425,273 shares traded hands during trading, a decline of 52% from the previous session’s volume of 895,292 shares.The stock last traded at $26.1560 and had previously closed at $26.06.

Analysts Set New Price Targets

A number of research analysts recently commented on XNCR shares. Royal Bank Of Canada upped their price objective on Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Wedbush lifted their target price on Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th. Finally, Wall Street Zen raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xencor has a consensus rating of “Hold” and an average target price of $24.86.

Xencor Stock Up 1.7%

The firm has a 50-day moving average price of $19.80 and a 200 day moving average price of $14.79. The firm has a market capitalization of $1.97 billion, a PE ratio of -12.22 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The firm had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the previous year, the business earned ($0.41) EPS. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. Equities research analysts expect that Xencor, Inc. will post -3 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its position in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares during the period. Allworth Financial LP purchased a new stake in shares of Xencor during the second quarter worth $55,000. E Fund Management Co. Ltd. acquired a new stake in shares of Xencor in the second quarter valued at $79,000. iSAM Funds UK Ltd acquired a new stake in shares of Xencor in the second quarter valued at $122,000. Finally, Prelude Capital Management LLC purchased a new position in Xencor in the third quarter valued at $139,000.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.